182 related articles for article (PubMed ID: 29755993)
1. The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature.
Mohammadpour F; Kargar M; Hadjibabaie M
J Res Pharm Pract; 2018; 7(1):4-12. PubMed ID: 29755993
[TBL] [Abstract][Full Text] [Related]
2. Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia.
Brik-Simon D; Efros O; Levinsky Y; Amarilyo G; Tirosh I; Levy-Mendelovich S; Steinberg-Shemer O; Izraeli S; Yacobovich J; Gilad O
Pediatr Blood Cancer; 2024 May; 71(5):e30911. PubMed ID: 38348516
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Khellaf M; Chabrol A; Mahevas M; Roudot-Thoraval F; Limal N; Languille L; Bierling P; Michel M; Godeau B
Am J Hematol; 2014 Feb; 89(2):194-8. PubMed ID: 24254965
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
5. Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis.
Pamuk ON; Ali SM; Hasni S
Autoimmun Rev; 2023 Apr; 22(4):103297. PubMed ID: 36781038
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia.
Li HJ; Zheng YQ; Chen L; Lin SP; Zheng XX
Ther Adv Chronic Dis; 2023; 14():20406223231160688. PubMed ID: 36969501
[TBL] [Abstract][Full Text] [Related]
7. Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities.
Bashyal KP; Shah S; Ghimire C; Balmuri S; Chaudhary P; Karki S; Poudel AK; Pokharel A; Devarkonda V; Hayat S
Int J Rheumatol; 2024; 2024():6650921. PubMed ID: 38464849
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis.
Zhou EM; Shen H; Wang D; Xu W
PeerJ; 2024; 12():e17152. PubMed ID: 38666084
[TBL] [Abstract][Full Text] [Related]
9. Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.
Song Y; Zhang Y; Li Z; Liu J; Xiao J; Song H
Ann Hematol; 2022 Jul; 101(7):1447-1456. PubMed ID: 35532821
[TBL] [Abstract][Full Text] [Related]
10. Comparison of platelet immunity in patients with SLE and with ITP.
Lazarus AH; Ellis J; Semple JW; Mody M; Crow AR; Freedman J
Transfus Sci; 2000; 22(1-2):19-27. PubMed ID: 10771375
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements.
Samuel H; Nardi M; Karpatkin M; Hart D; Belmont M; Karpatkin S
Br J Haematol; 1999 Jun; 105(4):1086-91. PubMed ID: 10554825
[TBL] [Abstract][Full Text] [Related]
12. Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients.
Roussotte M; Gerfaud-Valentin M; Hot A; Audia S; Bonnotte B; Thibault T; Lobbes H; Le Guenno G; Goulabchand R; Cathebras P; Varron L; Dufour JF; Deroux A; Compain C; Baudet A; Karkowski L; Pérard L; Ebbo M; Lega JC; Sève P
Rheumatology (Oxford); 2022 Aug; 61(9):3627-3639. PubMed ID: 34918048
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia.
Ahn SM; Choi EJ; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
Arthritis Res Ther; 2022 Sep; 24(1):213. PubMed ID: 36068638
[TBL] [Abstract][Full Text] [Related]
14. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.
Nord JE; Shah PK; Rinaldi RZ; Weisman MH
Semin Arthritis Rheum; 2004 Apr; 33(5):336-51. PubMed ID: 15079764
[TBL] [Abstract][Full Text] [Related]
16. Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia.
Zhan Y; Cheng L; Wu B; Ji L; Chen P; Li F; Cao J; Ke Y; Yuan L; Min Z; Sun L; Chen H; Hua F; Cheng Y
Ann Transl Med; 2021 Feb; 9(3):222. PubMed ID: 33708849
[TBL] [Abstract][Full Text] [Related]
17. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
Jallouli M; Galicier L; Zahr N; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Le Thi Huong D; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Leroux G; Cohen-Bittan J; Sellam J; Mariette X; Blanchet B; Hulot JS; Amoura Z; Piette JC; Costedoat-Chalumeau N;
Arthritis Rheumatol; 2015 May; 67(8):2176-84. PubMed ID: 25989906
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sjögren syndrome.
Sun F; Tang Q; Cheng W; Xie X; Li F; Chen J
Int Immunopharmacol; 2023 Oct; 123():110716. PubMed ID: 37506503
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.
Dima A; Jurcut C; Chasset F; Felten R; Arnaud L
Ther Adv Musculoskelet Dis; 2022; 14():1759720X211073001. PubMed ID: 35186126
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
